On Jun. 24, 2020, RedHill Biopharma announced that results from the treatment of the first severe COVID-19 patients with its investigational drug, opaganib (Yelivaﾮ, ABC294640)1, were published in medRxiv.

Seven patients with severe COVID-19 were treated with opaganib under compassionate use in a leading hospital in Israel.

All patients in the opaganib-treated group were discharged from hospital on room air, without having required mechanical ventilation, whereas 33% of patients in the control group required mechanical ventilation.